Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S214010, C514S214020, C514S210210, C514S210200, C514S210100, C514S210050
Reexamination Certificate
active
09486613
ABSTRACT:
The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
REFERENCES:
patent: 3516989 (1970-06-01), Sallay
patent: 3557126 (1971-01-01), Sallay
patent: 3574220 (1971-04-01), Sallay
patent: 3639408 (1972-02-01), Nagata et al.
patent: 3715361 (1973-02-01), Epstein et al.
patent: 3875011 (1975-04-01), Rubenstein et al.
patent: 4272541 (1981-06-01), Kotick et al.
patent: 4375414 (1983-03-01), Strahilevitz
patent: 4444758 (1984-04-01), Scherschlicht et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4464378 (1984-08-01), Hussain
patent: 4499096 (1985-02-01), Lotsof
patent: 4587243 (1986-05-01), Lotsof
patent: 4604365 (1986-08-01), O'Neill et al.
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4661492 (1987-04-01), Lewis et al.
patent: 4857523 (1989-08-01), Lotsof
patent: 5026697 (1991-06-01), Lotsof
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5149538 (1992-09-01), Granger et al.
patent: 5152994 (1992-10-01), Lotsof
patent: 5283247 (1994-02-01), Dwivedi et al.
patent: 5290784 (1994-03-01), Qu et al.
patent: 5316759 (1994-05-01), Rose et al.
patent: 5426112 (1995-06-01), Zagon et al.
patent: 5552406 (1996-09-01), Mendelson et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5580876 (1996-12-01), Crain et al.
patent: 5591738 (1997-01-01), Lotsof
patent: 5618555 (1997-04-01), Tokuda et al.
patent: 5703101 (1997-12-01), Rose et al.
patent: 5726190 (1998-03-01), Rose et al.
patent: 5760044 (1998-06-01), Archer
patent: 5861422 (1999-01-01), Rose et al.
patent: 5925634 (1999-07-01), Olney
patent: 5935975 (1999-08-01), Rose et al.
patent: 6348456 (2002-02-01), Mash et al.
patent: 2217132 (1972-10-01), None
patent: 841697 (1960-07-01), None
patent: 924042 (1963-04-01), None
patent: 1256914 (1971-12-01), None
patent: 2271059 (1994-04-01), None
patent: 4221315 (1992-08-01), None
patent: WO 91/18609 (1991-12-01), None
patent: WO 93/20825 (1993-10-01), None
patent: WO 93/25217 (1993-12-01), None
patent: WO 94/06426 (1994-03-01), None
patent: WO 94/14490 (1994-07-01), None
patent: WO 96/03127 (1996-02-01), None
patent: WO9603127 (1996-02-01), None
Hardman et al. “Goodman & Gilman's The Parmacological Basis of Therapeutics” (9th ed, 1996) p. 51 and 57-58.
Mash et al, Properties of Ibogaine and its Principle Metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex, 1995, Neuroscience Letters, 192, 53-56.
Pablo et al, Noribogaine Stimulates Naloxone-Sensitive[35S]GTPgammaS Binding, 1998, NeuroReport, 9, pp. 109-114. (Website Publication Date of Dec. 20, 1997.).
Mark J. Millan, k-Opioid Receptors and Analgesia, 1990, Trendes in Pharmacologicla Sciences, 11, pp. 70-76.
Pablo, John P. and Mash, Deborah C. “Noribogaine Stimulates Naloxane-Sesitive [35S]GTPγS Binding”,NeuroReport, 9: pp. 109-114, 1998.
Bagal et al. “Modulation of Morphine-Induced Antinociception by Ibogaine and Noribogaine”,Brain Research, 741: pp. 258-262, 1996.
Bundgaard, Hans. “Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities”,Design of Prodrugs, (New York, Elsevier Science Publishers, 1985).
Schuckit, M. A. et al. “Opioid Drug Use”, in Isselbacher, K.J. et al.,Harrisoné Principles of Internal Medicine(New York, McGraw-Hill, 1994) pp. 2425-2429.
Holbrook, J. H. “Nicotine Addiction”, in Isselbacher K.J. et al.,Harrison's Principles of Internal Medicine, (New York, McGraw-Hill, 1994) pp. 2433-2437.
Jaffe, J. H. “Drug Addiction and Drug Abuse”, in Gilman A.G. et al.,Goodman and Gilman's The Pharmacological Basis of Therapeutics, (New York, Pergamon Press, 1990) pp. 520-523 and pp. 559-568.
Stella, V. “Pro-drugs as Novel Drug Delivery Systems”, Higuchi, T. et al., ed. (American Chemical Society, Washington), pp. 1-49 (1975).
Maisonneuve, I. M. et al. “Interactions of Ibogaine and D-Amphetamine: in Vivo Microdialysis and Motor Behavior in Rats”,Brain Research, 579: pp. 87-92, 1992.
Benet, L. Z. et al. “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination”, in Gilman, A.G. et al.,Goodman and Gilman's The Pharmacological Basics of Therapeutics, (New York, Pergamon Press, 1990), pp. 13-16.
Bartlett, M. F. et al. “The Alkaloids ofTabernanthe iboga. Part IV.1The Structures of Ibogamine, Ibogaine, Tabernanthine and Voacangine”,J. Am. Chem. Soc., 80: pp. 126-136, 1958.
Kornetsky, Conan. “Pharmacology Drugs Affecting Behavior”, (New York, John Wiley & Sons, 1976), pp. 186.
Deecher, D. C. et al. “Mechanisms of Action of Ibogaine and Harmaline Congeners Based on Radioligand Binding Studies”,Brain Research, 571(2): pp. 242-247, 1992.
Sinkula, A. A. et al. “Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs”,Journal of Pharmaceutical Sciences, 64: pp. 181-210, Feb. 1975.
Zetler, G. et al. “Pharmacokinetic in the Rat of the Hallucinogenic Alkaloids Harmine and Harmaline”,Naunyn-Schmiedeberg's Arch. Pharmacol., 285: pp. 273-292, 1974.
Glick, S. D. et al. “Effects ofibogaAlkaloids on Morphine and Cocaine Self-Administration in Rats: Relationship to Tremorigenic Effects and to Effects on Dopamine Release in Nucleus Accumbens and Striatum”,Brain Research, 657: pp. 14-22, 1994.
Cappendijk, Susanne et al. “The Inhibitory Effect of Norharman on Morphine Withdrawal Syndrome in Rats: Comparisons with Ibogaine”,Behavioural Brain Research, Faculty of Medicine and Health Sciences, Eramus University Rotterdam, 3000 Dr., Rotterdam, The Netherlands, Aug. 5, 1994, pp. 1-3.
Gunn. J. A. “Relations Between Chemical Constitution, Pharmacological Actions, and Therapeutic Uses, in the Harmine Group of Alkaloids”,The Pharmacological Laboratory, University of Oxford, Mar. 14, 1935, pp. 379-383, pp. 395-396.
Slotkin, Theodore A. and DiStefano, Victor. “A Model of Harmine Metabolism in the Rat”,The Journal of Pharmacology and Experimental Therapeutics, Department of Pharmacology, University of Rochester, Rochester, New York, The Williams & Wilkins Co., 174(3): pp. 456-462, 1970.
Ho, Beng T. et al. “Metabolish of Harmaline in Rats”,Biochemical Pharmacology, 20: pp. 1313-1319, 1971.
Slotkin, Theodore A. et al. “Blood Levels and Urinary Excretion of Harmine and Its Metabolites in Man and Rats”,The Journal of Pharmacology and Experimental Therapeutics, 173(1): pp. 26-30, 1970.
Slotkin, Theodore and DiStefano, Victor. “Urinary Metabolites of Harmine in the Rat and Their Inhibition of Monoamine Oxidase”,Biochemical Pharmacology, 19: pp. 125-131, 1970.
Glick, S. D. et al. “Effects of Aftereffects of Ibogaine on Morphine Self-Administration in Rats”,European Journal of Pharmacology, 195(3): abstract only, 1991.
Dzoljic, E. D. et al. “Effect of Ibogaine on Naloxone-Precipitated Withdrawal Syndrome in Chronic Morphine-Dependent Rats”,Archives Internationales de Pharmacodynamie et de Therapie, 294: abstract only, 1988.
Schechter, M. D. et al. “Comparison of the Behavioral Effects of Ibogaine from Three Sources: Mediation of Discriminative Activity”,European Jornal of Pharmacology, 249(1): abstract only, 1993.
Popik, P. et al. “The Putative Anti-Addictive Drug Ibogaine is a Competitive Inhibitor of ( SUP 3 H) Binding to the NMDA Receptor Complex”,Psychopharmacologia, 114(4): abstract only, 1994.
Harsing, L.G. Jr. et al. “Evidence that Ibogaine Releases Dopamine from the Cytoplasmic Pool in Isloated Mouse Striatum”,Journal of Neural Transmission General Section, 96(3): abstract only, 1994.
Cappendijk, Susanne L. T. and Dzoljic, Michailo R. “In
Coleman Henry D.
Cotton Abigail M.
Novoneuron, Inc
Padmanabhan Sreeni
Sapone William J.
LandOfFree
Noribogaine in the treatment of pain and drug addiction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Noribogaine in the treatment of pain and drug addiction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Noribogaine in the treatment of pain and drug addiction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3759328